AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical stage biopharmaceutical company, announced its financial results for the fourth quarter and year ended December 31, 2025. The company reported a net loss of $35.2 million for the full year, a decrease from $51.3 million in 2024. For Q4 2025, the net loss was $8.7 million, compared to $7.5 million in the same period last year. Research and development expenses for 2025 were $24.8 million, down from $40.5 million in 2024, while general and administrative expenses decreased slightly to $13.3 million from $14.1 million. The company highlighted its ongoing clinical trials, including a Phase 2 study of oral epetraborole for polycythemia vera expected to begin in Q3 2026, with data readouts anticipated in late 2026 and throughout 2027. Additionally, AN2 is advancing a Phase 2 trial for epetraborole in M.abscessus complex lung disease, with enrollment expected to start in Q1 2026. The company also reported progress in its Chagas disease program, with initial clinical data from a Phase 1 trial of oral AN2-502998 expected in Q1 2026. The company’s cash position was reported at $60 million as of December 31, 2025, with a recent private placement expected to extend its runway into 2029. AN2 Therapeutics remains committed to delivering impactful therapies to patients with urgent unmet needs.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.